Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer

December 12th 2025

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

CAPItello-291 Analysis Reveals Potential Utility of PIK3CA/AKT1/PTEN Alteration Detection Via ctDNA in Advanced HR+ Breast Cancer

December 11th 2025

Circulating tumor DNA could represent a minimally invasive approach for detecting AKT pathway alterations in hormone receptor–positive breast cancer.

Maintenance Tucatinib Plus HP Extends Median PFS Beyond 2 Years in Advanced HER2+ Breast Cancer

December 11th 2025

Tucatinib plus HP improved median investigator-assessed PFS by 8.6 months as first-line maintenance vs HP alone in HER2-positive metastatic breast cancer.

Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer

December 10th 2025

Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.

Dr Tolaney on the Design of the ELEGANT Trial in ER+, HER2-Negative Early Breast Cancer

December 10th 2025

Sara M. Tolaney, MD, MPH, discusses the design and potential significance of the ongoing ELEGANT trial of elacestrant in ER-positive early breast cancer.

AJ1-11095 Receives Orphan Drug Designation From the FDA in Myelofibrosis

December 10th 2025

AJ1-11095 received orphan drug designation from the FDA in myelofibrosis.

Limited-Duration Teclistamab Drives Durable Responses in Relapsed/Refractory Myeloma

December 9th 2025

Early teclistamab discontinuation after deep response showed PFS comparable to continuous therapy in relapsed/refractory myeloma in the LimiTEC trial.

FDA Approves Omidubicel for Adult and Pediatric Patients With Severe Aplastic Anemia

December 9th 2025

The FDA has approved the HSCT therapy for patients 6 years or older with SAA following reduced-intensity conditioning who do not have a compatible donor.

Sonrotoclax Displays Activity in BTK Inhibitor–Pretreated R/R MCL

December 8th 2025

Sonrotoclax monotherapy led to an ORR of 52.4% and a CR rate of 15.5% in relapsed/refractory MCL.

Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis

December 7th 2025

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

Zanubrutinib Demonstrates Long-Term Efficacy, Safety in Relapsed/Refractory CLL/SLL

December 7th 2025

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Real-World Data Suggest ctDNA Status More Accurately Captures EFS Outcomes Than PET-CT

December 6th 2025

ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.

Zanubrutinib Plus R-CHOP Is Active in Untreated DLBCL With Specific Gene Expression

December 6th 2025

Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.

Experts Prepare for Several Key MCL Presentations at ASH 2025

December 5th 2025

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC

December 5th 2025

Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

Loncastuximab Tesirine Plus Glofitamab Yields High CR Rates in DLBCL in Updated LOTIS-7 Analysis

December 4th 2025

Adding loncastuximab tesirine to glofitamab led to activity irrespective of disease status in relapsed/refractory diffuse large B-cell lymphoma.

Lutetium Lu 177 Vipivotide Tetraxetan Shows Activity in Oligometastatic HSPC

December 2nd 2025

Lutetium Lu 177 vipivotide tetraxetan was effective in patients with oligometastatic hormone-sensitive prostate cancer.

ctDNA Insights Stand at the Forefront of Data-Driven, Individualized MIBC Management

November 25th 2025

In a recent Peer Exchange, bladder cancer experts reviewed the current treatment paradigm for muscle-invasive bladder cancer (MIBC) and discussed updates from ESMO 2025.

The Essential but Often Complex Role of Numbers and Measurements in Oncology

November 20th 2025

Maurie Markman, MD, discusses the evolving role of measurements in cancer care.